Insmed Incorporated research snapshot
INSM AI stock analysis currently sees Insmed as a commercial-stage rare-disease company with a fast BRINSUPRI launch, a growing ARIKAYCE franchise, and important pipeline optionality in respiratory disease. At the July 11, 2026 cutoff, INSM traded near $118.19 with a verified market capitalization of $25.63 billion. The core tension is that sales growth and guidance are strong, while the company remains loss-making, uses substantial cash, carries debt and royalty obligations, and depends on sustained uptake, reimbursement, regulatory execution, and clinical progress. This page is informational only and not investment advice.
Current price
$118.19
Market cap
$25.63 billion
AI score
58 / 100
Rating
Commercial momentum is strong, but execution and valuation risk remain high
Trend status
Recovery above the 50-day average, still below the 200-day average
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Insmed sells specialty respiratory therapies for underserved patient groups. BRINSUPRI and ARIKAYCE can create recurring treatment revenue, but demand depends on diagnosis, access, prescriber adoption, and adherence. | Medium-high |
| Moat | Regulatory approvals, orphan-disease expertise, physician relationships, clinical data, manufacturing know-how, and a direct commercial footprint create barriers. The moat remains product-specific rather than a broad platform lock-in. | Medium |
| Management | Chair and CEO Will Lewis has guided the BRINSUPRI launch and expanded the respiratory pipeline. The key test is balancing commercial investment and clinical development with a credible path to lower cash burn. | Medium |
| Financial trend | FY2025 revenue was $606.4 million, up 66.7%, and Q1 2026 revenue was $306.0 million, up about 230% year over year. Q1 still produced a $163.6 million net loss and $222.7 million operating cash use. | High |
| Valuation | At $118.19, INSM had a $25.63 billion market cap and negative TTM earnings and free cash flow. Conventional P/E and P/FCF do not provide a margin-of-safety signal, so the valuation rests on future product sales and pipeline value. | High |
| Technical trend | INSM was above its 50-day moving average near $109.49 but below its 200-day average near $151.16. RSI near 67 showed improving momentum without a confirmed long-term uptrend. | Medium-high |
| Risk level | Risk is high. Reimbursement, commercialization, supply, regulatory decisions, clinical trial outcomes, cash burn, debt, royalty financing, dilution, and competition can all materially change value. | High |
| AI confidence | Reported financial and product data are well documented, but AI cannot know future payer behavior, patient identification, clinical outcomes, or market sentiment. | High data confidence |
| Investment certainty | Investment certainty is lower than data confidence because a large portion of the valuation depends on revenue that has not yet been earned and clinical programs that have not yet read out. | Low-medium |
INSM AI stock forecast
The INSM AI stock forecast uses scenarios instead of a promised price. The auditable three-year model applies illustrative normalized EPS of $1.50, growth rates of 40%, 25%, and 10%, and terminal P/E multiples of 45x, 30x, and 18x. These are valuation assumptions, not company guidance, because INSM currently reports a net loss.
$170 to $190
More likely if BRINSUPRI exceeds the at-least-$1 billion 2026 revenue guide, international access expands, ARIKAYCE label expansion improves the addressable market, TPIP data support a large opportunity, and operating leverage becomes visible.
$80 to $95
More likely if BRINSUPRI and ARIKAYCE broadly meet expectations but commercial spending and pipeline investment delay profitability, while the market applies a lower multiple to longer-dated earnings.
$30 to $45
More likely if payer access, diagnosis expansion, persistence, or international launches disappoint, if a key study or regulatory event weakens the pipeline, or if cash burn and financing needs rise before earnings scale.
INSM AI technical analysis
INSM AI technical analysis uses the July 10, 2026 StockAnalysis market snapshot. The static page does not fetch live market data. The price reference of $118.19 was above the 50-day average but below the 200-day average, so the setup is a recovery trade rather than confirmation of a long-term breakout.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $118.19 | Quote snapshot used for the July 11, 2026 analysis and market-cap calculation. |
| Near support | $109 to $110 | The 50-day moving average was $109.49. A live chart should confirm whether this area attracts demand. |
| Secondary support | $100 | A round-number reference below the 50-day average. It is a monitoring level, not a guaranteed floor. |
| Long-term resistance | $151 to $152 | The 200-day moving average was $151.16. A sustained move above it would improve the long-term trend case. |
| Momentum | RSI 67.03 | Momentum had improved but was approaching an extended reading. It should be reviewed with live price and news. |
| Volume | 4.60 million average shares | StockAnalysis reported 20-day average volume of 4,595,398 shares. Breakouts need confirming volume. |
| Volatility | Beta 0.78, event-driven | Reported beta was below one, but drug, regulatory, earnings, and financing events can still produce sharp gaps. |
| Short interest | 8.60% of shares outstanding | Short interest can add volatility around news but is not an investment signal by itself. |
| Invalidation | Sustained close below $109 | A sustained close below the 50-day average weakens the recovery framework and should trigger a review of price action and fundamentals. |
INSM AI trading strategy
The INSM AI trading strategy is a research and risk-control framework, not a personalized recommendation. It combines live chart confirmation with quarterly revenue, payer access, patient starts, cash use, financing, regulatory dates, and clinical milestones.
Monitor whether INSM holds above the 50-day moving average and later reclaims the 200-day average with volume. Confirm the price action with new evidence of BRINSUPRI uptake and no deterioration in cash or guidance.
A sustained close below about $109 weakens the setup. Size exposure for biotechnology event gaps rather than relying on a tight stop alone.
If INSM retreats toward the 50-day average without a negative product, payer, regulatory, or trial update, compare the price change with the next revenue report, patient-start data, and cash-use trend.
Do not assume a support level will hold when the underlying news changes. Missed guidance or a negative clinical event can make a technical pullback fundamental.
Track BRINSUPRI sales against the at-least-$1 billion guide, ARIKAYCE guidance, cash and marketable securities, operating cash use, term-loan and royalty obligations, ENCORE label progress, TPIP trials, and new financing.
Reduce confidence if commercial growth slows while operating cash use stays high, if access or adherence weakens, or if pipeline timelines extend without stronger evidence.
Investment research summary
Insmed develops and commercializes therapies for serious, underserved diseases. Customers and payers pay when products show clinical value, gain coverage, reach identified patients, and are manufactured and supplied reliably.
The moat comes from orphan and respiratory disease expertise, approval history, clinical evidence, prescriber education, specialty distribution, and manufacturing. It can narrow if competing therapies offer better efficacy, safety, convenience, or price.
The thesis fails if BRINSUPRI uptake falls short, reimbursement or diagnosis expansion is slower than expected, ARIKAYCE demand weakens, clinical programs disappoint, safety or supply issues emerge, or cash needs force further dilutive financing.
Management has turned Insmed into a two-product commercial company while advancing a wider pipeline. The next capital-allocation test is whether commercial and R&D spending translate into durable operating leverage before liquidity becomes a concern.
Rare respiratory and inflammatory disease treatment benefits from better diagnosis, targeted therapy, and specialist care. The opportunity is meaningful, but markets can be constrained by payer rules, patient finding, competition, and trial execution.
The market is valuing expected future BRINSUPRI, ARIKAYCE, and pipeline cash flows rather than present earnings. Margin of safety is limited until sales durability, cash burn improvement, and a path to profitability become clearer.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| INSM price | $118.19 | StockAnalysis quote snapshot | July 11, 2026 |
| Market capitalization | $25.63 billion, verified as $118.19 x 216.75 million shares | financial_rigor.py and StockAnalysis | July 11, 2026 |
| FY2025 revenue | $606.4 million, up 66.7% year over year | Insmed 2025 annual report and Macrotrends cross-check | July 11, 2026 |
| Q1 2026 revenue | $306.0 million, including $207.9 million BRINSUPRI and $98.1 million ARIKAYCE | Insmed Q1 2026 financial results and StockAnalysis cross-check | July 11, 2026 |
| Cash and marketable securities | $1.22 billion at March 31, 2026 | Insmed Q1 release and StockAnalysis cross-check | July 11, 2026 |
| Debt | $742.46 million total debt; $481.05 million net cash | StockAnalysis balance sheet and SEC Form 10-Q | July 11, 2026 |
| Operating cash use | $222.7 million in Q1 2026 | SEC Form 10-Q | July 11, 2026 |
| Valuation math | P/E and P/FCF are not meaningful with negative TTM EPS and free cash flow; P/B about 34.76x | financial_rigor.py valuation verification | July 11, 2026 |
| Technical inputs | 50-day MA $109.49, 200-day MA $151.16, RSI 67.03, 20-day average volume 4.60 million | StockAnalysis statistics | July 11, 2026 |
This INSM AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, tax advice, a recommendation, or a promise of future returns. Forecast ranges are scenarios based on available public filings, quote snapshots, technical data, and third-party sources as of July 11, 2026. They may be wrong, incomplete, or outdated after new earnings, product sales, payer updates, clinical data, regulatory decisions, financing, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
